Pfizer’s Ibrance flunks early breast cancer trial
Therapy failed to improve invasive disease-free survival in high-risk patients
Read More
Tag: Ibrance
Pfizer’s Ibrance ‘unlikely’ to hit key early breast cancer goal
The trial is unlikely to show a statistically significant improvement in invasive disease-free survival
Read More
Ibrance given NICE green light in breast cancer
The recommendation is based on data from the Phase III clinical trial, PALOMA-3, in which Ibrance delayed disease progression by 6.6 months.
Read MorePfizer’s Ibrance extended for use in men by FDA
Pfizer’s Ibrance will now be available to male patients with metastatic breast cancer.
Read More
Scotland approves NHS funding for Ibrance, Cerdelga and Invicorp
The latest batch of decisions by the Scottish Medicines Consortium has given patients with certain forms of breast cancer, Gaucher disease and erectile dysfunction new treatment options on the NHS.
Read More
NICE waves through breast cancer drugs following price deals
The National Institute for Health and Care Excellence is backing routine NHS funding for Pfizer’s Ibrance and Novartis’ Kisqali to treat certain forms of breast cancer, after the firms agreed to provide them at a reduced price under the new process for appraising medicines.
Read More
Pfizer offers Ibrance free to the NHS during NICE appraisal
Pfizer is to offer its breast cancer drug Ibrance free to the NHS while cost regulators decide whether it should be routinely funded in England and Wales.
Read More
Pfizer’s Ibrance too expensive for NHS use
Cost regulators for the NHS in England and Wales have ruled that Pfizer’s Ibrance is too costly in relation to its benefits as a treatment for breast cancer to be funded by the health service.
Read More
Pfizer bags EU approval for breast cancer drug Ibrance
European regulators have cleared use of Pfizer’s Ibrance to treat women with locally advanced or metastatic breast cancer that is hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative.
Read More
Ten medicines leap towards EU approval
Ten new medicines have taken a giant leap closer to European Union approval after having won the backing of the Committee for Medicinal Products for Human Use.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
